Severity
Moderate
FDA Drug recall · Reported February 19, 2020
CGMP deviations: Product bottle may be absent of desiccant.
Teva Pharmaceuticals USA recalled Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle,… - a moderate-severity action.
Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle,… was recalled by Teva Pharmaceuticals USA in February 19, 2020. Reason: CGMP deviations: Product bottle may be absent of desiccant.. Check the official notice for the remedy. Verify recall #D-0836-2020 with the FDA Drug before acting.
The recall
Teva Pharmaceuticals USA issued this moderate-severity FDA Drug recall-CGMP deviations: Product bottle may be absent of desiccant..
Sourced from official FDA Drug enforcement records. Verify recall #D-0836-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0836-2020) was formally reported on February 19, 2020, with the manufacturer initiating the action on January 27, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Teva Pharmaceuticals USA is listed as the recalling firm, operating out of Parsippany, NJ. The number of affected units is not disclosed in the agency filing, which is common for drug and food recalls where lot-level tracking supersedes unit counts.
The documented reason for this recall is: CGMP deviations: Product bottle may be absent of desiccant. Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
Unknown
Related Recalls
6
0 from same agency
Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 62037-725-01
CGMP deviations: Product bottle may be absent of desiccant.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0836-2020 |
| Date reported | February 19, 2020 |
| Date initiated | January 27, 2020 |
| Recalling firm | Teva Pharmaceuticals USA |
| Firm location | Parsippany, NJ |
| Affected scope | Not disclosed |
| Distribution | USA Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 19, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.